Assyro AI

Orange Book product · Brand (NDA)

AXTLE

PEMETREXED DIPOTASSIUM

Brand (NDA)NDA 210661RX AVYXA HOLDINGS

At a glance

Jun 28, 2024

Approved

Brand (NDA)

Application

Not listed

TE code

None

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jun 28, 2024

    2 yr ago

  2. Today

Pharmaceutical detail

Active ingredient

PEMETREXED DIPOTASSIUM

Strength

EQ 100MG BASE/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 210661

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.